MoonLake Immunotherapeutics
|
Dec-25 |
Dec-24 |
Dec-23 |
Dec-22 |
Dec-21 |
Dec-20 |
| Total revenue |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
| Cost of revenue |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Gross profit |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Selling, general and administrative |
0.04 |
0.03 |
0.02 |
0.02 |
0.00 |
|
| Research and development |
0.20 |
0.11 |
0.03 |
0.04 |
0.04 |
|
| Other operating expenses |
0.00 |
0.00 |
0.00 |
0.00 |
-0.04 |
0.00 |
| Operating income |
-0.24 |
-0.14 |
-0.05 |
-0.07 |
0.00 |
0.00 |
| Non-operating income (net) |
0.02 |
0.02 |
0.01 |
0.00 |
0.00 |
0.00 |
| Income before tax |
-0.23 |
-0.12 |
-0.04 |
-0.06 |
0.00 |
0.00 |
| Income tax expense |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Net income |
-0.23 |
-0.12 |
-0.04 |
-0.06 |
0.00 |
0.00 |
Show Quarterly Income Statement
|
Mar-26 |
Dec-25 |
Sep-25 |
Jun-25 |
Mar-25 |
Dec-24 |
Sep-24 |
Jun-24 |
Mar-24 |
Dec-23 |
Sep-23 |
Jun-23 |
Mar-23 |
Dec-22 |
Sep-22 |
Jun-22 |
Mar-22 |
Dec-21 |
Sep-21 |
Jun-21 |
Mar-21 |
Dec-20 |
| Total revenue |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
0.00 |
0.00 |
|
|
| Cost of revenue |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
0.00 |
|
|
|
|
| Gross profit |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
0.00 |
|
|
|
|
| Selling, general and administrative |
0.02 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.00 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.00 |
|
|
| Research and development |
0.05 |
0.06 |
0.06 |
0.05 |
0.04 |
0.04 |
0.04 |
0.02 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.00 |
0.00 |
0.03 |
|
|
| Other operating expenses |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Operating income |
-0.07 |
-0.07 |
-0.07 |
-0.06 |
-0.05 |
-0.05 |
-0.04 |
-0.03 |
-0.02 |
-0.02 |
-0.01 |
-0.01 |
-0.01 |
-0.02 |
-0.01 |
-0.02 |
-0.02 |
-0.01 |
-0.01 |
-0.03 |
0.00 |
0.00 |
| Non-operating income (net) |
0.00 |
0.00 |
0.00 |
0.00 |
0.01 |
0.00 |
0.01 |
0.01 |
0.01 |
0.01 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Income before tax |
-0.07 |
-0.06 |
-0.07 |
-0.06 |
-0.04 |
-0.05 |
-0.04 |
-0.02 |
-0.01 |
-0.01 |
-0.01 |
-0.01 |
-0.01 |
-0.02 |
-0.01 |
-0.02 |
-0.02 |
-0.01 |
-0.01 |
-0.03 |
0.00 |
0.00 |
| Income tax expense |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
0.00 |
0.00 |
|
| Net income |
-0.07 |
-0.06 |
-0.07 |
-0.06 |
-0.04 |
-0.05 |
-0.04 |
-0.02 |
-0.01 |
-0.01 |
-0.01 |
-0.01 |
-0.01 |
0.00 |
-0.01 |
-0.01 |
-0.02 |
-0.01 |
-0.01 |
-0.03 |
0.00 |
0.00 |
|
Dec-25 |
Dec-24 |
Dec-23 |
Dec-22 |
Dec-21 |
Dec-20 |
| Cash and cash equivalents |
0.33 |
0.18 |
0.45 |
0.04 |
0.01 |
0.00 |
| Short-term investments |
0.06 |
0.27 |
0.06 |
0.03 |
0.00 |
|
| Accounts receivable, net |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Inventories |
|
|
|
|
0.00 |
|
| Other current assets |
0.02 |
0.02 |
0.00 |
0.00 |
0.00 |
0.00 |
| Total current assets |
0.42 |
0.47 |
0.51 |
0.08 |
0.01 |
0.00 |
| Property, plant and equipment, net |
|
|
|
0.00 |
0.00 |
|
| Goodwill |
|
|
|
|
|
|
| Intangible assets |
|
|
|
|
|
|
| Long-term investments |
|
|
|
|
|
|
| Other non-current assets |
|
|
|
|
|
|
| Total assets |
0.42 |
0.48 |
0.53 |
0.08 |
0.01 |
0.12 |
|
| Accounts payable |
0.03 |
0.01 |
0.00 |
0.00 |
0.00 |
|
| Short-term debt |
0.00 |
0.00 |
0.00 |
0.00 |
0.02 |
0.00 |
| Current portion of long-term debt |
|
|
|
|
0.02 |
|
| Deferred revenue |
|
|
|
|
|
|
| Other current liabilities |
0.04 |
0.01 |
0.01 |
0.01 |
0.00 |
0.00 |
| Long-term debt |
0.07 |
|
|
|
|
|
| Capital lease obligations |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Other non-current liabilities |
|
|
|
0.00 |
|
|
| Total liabilities |
0.12 |
0.02 |
0.01 |
0.01 |
0.02 |
0.00 |
|
| Common stock and paid-in capital |
0.77 |
0.68 |
0.61 |
0.13 |
0.04 |
0.12 |
| Retained earnings |
-0.46 |
-0.24 |
-0.12 |
-0.08 |
-0.05 |
0.00 |
| Common shares outstanding |
64 |
63 |
49 |
29 |
37 |
15 |
Show Quarterly Balance Sheet
|
Mar-26 |
Dec-25 |
Sep-25 |
Jun-25 |
Mar-25 |
Dec-24 |
Sep-24 |
Jun-24 |
Mar-24 |
Dec-23 |
Sep-23 |
Jun-23 |
Mar-23 |
Dec-22 |
Sep-22 |
Jun-22 |
Mar-22 |
Dec-21 |
Sep-21 |
Jun-21 |
Mar-21 |
Dec-20 |
| Cash and cash equivalents |
0.30 |
0.33 |
0.35 |
0.31 |
0.27 |
0.18 |
0.38 |
0.34 |
0.46 |
0.45 |
0.32 |
0.50 |
0.05 |
0.04 |
0.04 |
0.09 |
0.10 |
0.01 |
0.00 |
0.00 |
0.00 |
|
| Short-term investments |
0.06 |
0.06 |
0.03 |
0.12 |
0.21 |
0.27 |
0.12 |
0.18 |
0.09 |
0.06 |
0.18 |
0.00 |
0.01 |
0.03 |
0.04 |
|
|
|
|
|
0.12 |
|
| Accounts receivable, net |
0.01 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.02 |
0.00 |
0.00 |
|
|
|
| Other current assets |
0.03 |
0.02 |
0.03 |
0.03 |
0.02 |
0.02 |
0.02 |
0.02 |
0.01 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.01 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Total current assets |
0.40 |
0.42 |
0.41 |
0.46 |
0.51 |
0.47 |
0.51 |
0.54 |
0.55 |
0.51 |
0.50 |
0.51 |
0.07 |
0.08 |
0.09 |
0.10 |
0.12 |
0.01 |
0.00 |
0.00 |
0.00 |
|
| Property, plant and equipment, net |
|
|
|
|
|
|
|
|
|
|
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
| Goodwill |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Long-term investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other non-current assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total assets |
0.40 |
0.42 |
0.41 |
0.46 |
0.51 |
0.48 |
0.52 |
0.54 |
0.56 |
0.53 |
0.50 |
0.51 |
0.07 |
0.08 |
0.09 |
0.10 |
0.23 |
0.01 |
0.12 |
0.12 |
0.12 |
|
|
| Accounts payable |
0.02 |
0.03 |
0.02 |
0.01 |
0.01 |
0.01 |
0.01 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
| Short-term debt |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.04 |
|
0.02 |
0.02 |
|
|
|
|
| Current portion of long-term debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.02 |
|
|
|
|
| Deferred revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other current liabilities |
0.05 |
0.04 |
0.05 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.00 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.00 |
0.19 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Long-term debt |
0.10 |
0.07 |
0.07 |
0.07 |
0.07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Capital lease obligations |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
| Other non-current liabilities |
|
|
|
|
|
|
|
|
|
|
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
| Total liabilities |
0.15 |
0.12 |
0.12 |
0.10 |
0.10 |
0.02 |
0.02 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.01 |
0.00 |
0.21 |
0.02 |
0.01 |
0.00 |
0.00 |
|
|
| Common stock and paid-in capital |
0.79 |
0.77 |
0.69 |
0.68 |
0.68 |
0.68 |
0.68 |
0.68 |
0.67 |
0.61 |
0.53 |
0.59 |
0.13 |
0.13 |
0.12 |
0.12 |
0.03 |
0.04 |
0.12 |
0.11 |
0.11 |
0.00 |
| Retained earnings |
-0.53 |
-0.46 |
-0.40 |
-0.33 |
-0.28 |
-0.24 |
-0.19 |
-0.15 |
-0.13 |
-0.12 |
-0.11 |
-0.10 |
-0.09 |
-0.08 |
-0.07 |
-0.06 |
-0.01 |
-0.05 |
0.00 |
0.00 |
0.00 |
|
| Common shares outstanding |
71 |
64 |
63 |
63 |
63 |
63 |
63 |
63 |
63 |
60 |
54 |
44 |
39 |
39 |
37 |
35 |
37 |
37 |
37 |
37 |
15 |
15 |
|
Dec-25 |
Dec-24 |
Dec-23 |
Dec-22 |
Dec-21 |
Dec-20 |
| Net income |
|
|
|
|
|
|
| Depreciation, depletion and amortization |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Stock-based compensation |
0.01 |
0.01 |
0.01 |
0.00 |
0.00 |
|
| Change in inventory |
|
|
|
|
|
|
| Other working capital changes |
-0.21 |
-0.13 |
-0.05 |
-0.06 |
-0.04 |
0.00 |
| Capital expenditures |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Others incl. marketable securities changes |
0.20 |
-0.21 |
-0.02 |
-0.03 |
0.00 |
-0.12 |
| Dividend payout |
|
|
|
|
0.00 |
|
| Common stock repurchases |
|
0.00 |
0.00 |
0.00 |
0.00 |
|
| Net Debt Issuance |
0.15 |
0.05 |
0.48 |
0.12 |
0.04 |
0.12 |
|
| Change in cash |
0.15 |
-0.27 |
0.41 |
0.03 |
0.01 |
0.00 |
Show Quarterly Cash Flow
|
Mar-26 |
Dec-25 |
Sep-25 |
Jun-25 |
Mar-25 |
Dec-24 |
Sep-24 |
Jun-24 |
Mar-24 |
Dec-23 |
Sep-23 |
Jun-23 |
Mar-23 |
Dec-22 |
Sep-22 |
Jun-22 |
Mar-22 |
Dec-21 |
Sep-21 |
Jun-21 |
Mar-21 |
| Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation, depletion and amortization |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
| Stock-based compensation |
0.01 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.01 |
0.00 |
0.00 |
|
| Change in inventory |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other working capital changes |
-0.08 |
-0.06 |
-0.05 |
-0.06 |
-0.04 |
-0.05 |
-0.03 |
-0.03 |
-0.02 |
-0.01 |
-0.01 |
-0.01 |
-0.01 |
-0.01 |
-0.01 |
-0.04 |
-0.02 |
-0.02 |
0.00 |
0.00 |
0.00 |
| Capital expenditures |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Others incl. marketable securities changes |
0.00 |
-0.03 |
0.09 |
0.09 |
0.06 |
-0.15 |
0.06 |
-0.09 |
-0.03 |
0.00 |
-0.17 |
0.01 |
0.02 |
0.01 |
-0.04 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Dividend payout |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock repurchases |
|
|
|
|
|
0.00 |
0.00 |
0.00 |
0.00 |
|
0.00 |
0.45 |
0.00 |
0.00 |
|
|
|
0.00 |
|
|
|
| Net Debt Issuance |
0.03 |
0.07 |
0.00 |
0.00 |
0.07 |
0.00 |
0.00 |
0.00 |
0.05 |
0.03 |
0.00 |
0.00 |
0.45 |
0.00 |
0.12 |
0.02 |
0.02 |
0.02 |
0.00 |
0.02 |
0.00 |
|
| Change in cash |
-0.04 |
-0.02 |
0.04 |
0.03 |
0.09 |
-0.20 |
0.03 |
-0.12 |
0.01 |
0.02 |
-0.18 |
0.45 |
0.46 |
0.00 |
0.07 |
-0.02 |
0.00 |
0.01 |
0.00 |
0.01 |
0.00 |
MoonLake Immunotherapeutics (MLTX) - Other Non Operating Income
MoonLake Immunotherapeutics (MLTX) - Net Income
MoonLake Immunotherapeutics (MLTX) - Ebitda
MoonLake Immunotherapeutics (MLTX) - Ebit
MoonLake Immunotherapeutics (MLTX) - Net Income From Continuing Operations
MoonLake Immunotherapeutics (MLTX) - Income Tax Expense
MoonLake Immunotherapeutics (MLTX) - Income Before Tax
MoonLake Immunotherapeutics (MLTX) - Depreciation And Amortization
MoonLake Immunotherapeutics (MLTX) - Interest Expense
MoonLake Immunotherapeutics (MLTX) - Net Interest Income